Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $128 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated a Neutral rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $128 price target.
February 15, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald maintains a Neutral rating and a $128 price target on Sarepta Therapeutics.
The reiteration of a Neutral rating and maintenance of the price target by a significant analyst firm like Cantor Fitzgerald suggests no immediate positive or negative catalysts for Sarepta Therapeutics' stock price in the short term. The analyst's view is likely based on a balanced assessment of the company's prospects, indicating stability but not significant growth potential in the near future.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90